CTOs on the Move

Westlake Medical Research

www.wmresearch.com

 
Westlake Medical Research is a Westlake Village, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.wmresearch.com
  • 1250 La Venta Dr Ste 101a
    Westlake Village, CA USA 91361
  • Phone: 805.496.3322

Executives

Name Title Contact Details

Similar Companies

BayStar EMS

BayStar EMS is a Baytown, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MED e-care Healthcare Solutions

MED e-care Healthcare Solutions Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elkhart General Healthcare System

For 100 years, the highly skilled professionals of Elkhart General Hospital have been providing comprehensive medical care to Elkhart and surrounding communities.

Blackline Marketing

Blackline Marketing specializes in helping clients in the hospitality, travel, restaurant, health care, business services, retail and food/beverage industries create integrated marketing solutions that increase revenues and maximize long-term customer engagement. Blackline Marketing helps clients in the areas of brand strategy, customer strategy, integrated marketing planning and people/process development. Clients include Northcott Hospitality/Houlihan`s restaurants, Caribou Coffee Company, HealthSource Solutions, ARC/Value Village Stores, Pebble Creek Golf Club and the MN Women`s Public Golf Association.

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.